Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Frequently asked questions
What sector does Cantargia AB (CANTA) operate in?
Cantargia AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cantargia AB (CANTA) current stock price?
As of the latest data, Cantargia AB stock price is SEK 1.80, with a previous close of SEK 1.81. Cantargia AB lost -SEK 0.00 in the last trading session, representing a -0.22% loss.
What is Cantargia AB (CANTA) current market capitalization?
Cantargia AB market cap is approximately 508.63 million.
What is Cantargia AB (CANTA) Earnings Per Share (EPS)?
The trailing EPS is SEK 0.64, and the forward EPS is -SEK 0.85.
What is Cantargia AB (CANTA) Price-to-Earnings (P/E) ratio?
Cantargia AB current P/E ratio is 2.82.
What is Cantargia AB (CANTA) EBITDA?
Cantargia AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -36.42 million.
Does Cantargia AB (CANTA) pay dividends?
No. Cantargia AB does not pay a dividend.
How did Cantargia AB (CANTA) perform in its most recent earnings report?
In the last report (March 31, 2026), Cantargia AB posted an EPS surprise of 27.78% and a revenue surprise of -76.91%.
When is Cantargia AB (CANTA) next earnings report?
Cantargia AB is expected to release its next earnings report on June 30, 2026.
What is Cantargia AB (CANTA) beta (volatility) score?
Cantargia AB has a beta of 1.588, suggesting it is more volatile than the market.
